-
The Evolving Role of Patient Advocacy
AACR’s Scientist↔Survivor Program marks a milestone as patient advocates continue to shape research and policy.
by Marci A. Landsmann
-
An Advocate’s Guide to Attending Scientific Meetings
Two graduates of the AACR Scientist↔Survivor Program share tips for getting the most out of large scientific conferences.
by Bob Riter and Carole Baas
-
Making Decisions About Breast Surgery
Patients who opt for breast reconstruction after mastectomy tend to overestimate how happy they will be with the results, while those who do not get reconstruction tend to underestimate their future satisfaction.
by Cici Zhang
-
A Better Way to Screen for Lynch Syndrome?
Researchers say a next-generation sequencing test could improve screening in colorectal cancer patients for a hereditary syndrome that raises cancer risk. Some experts have concerns.
by Cheryl Platzman Weinstock
-
Making Sense of Cancer Progress
Cancer Today editor Kevin McLaughlin contemplates what it means to report on cancer research advances when so many continue to die of the disease.
by Kevin McLaughlin
-
A Book Club for Cancer Survivors and Caregivers
Share your experiences as we discuss “A Cure Within” in a Cancer Today Facebook group.
by Marci A. Landsmann
-
Online Discussions Reveal Little-Known Side Effects
Analyzing online patient conversations could shed light on adverse drug reactions.
by Brad Jones
-
Is 3-D Mammography Better?
A study enrolling patients compares a newer form of digital mammography to conventional 2-D digital mammography.
by Marci A. Landsmann
-
When Cancer Survivors Get Another Cancer
Patients diagnosed with a second cancer may be unnecessarily excluded from clinical trials.
by Kate Yandell
-
Chemotherapy Essentials
Stock your bag with these useful items before your next infusion session.
by Jamie L. Schwachter
Cancer Talk
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live Longer
Findings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
2024: The Year in Cancer NewsThe Cancer Today editors share the most impactful reporting on cancer research from 2024.
by Cancer Today staff
Cancer Today Editors’ Picks: 2024Our favorite Cancer Today stories from 2024, as picked by the editors.